Overview
Registration
Agenda
Faculty
View Archive

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Lilly.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com

Pathology Essentials: RET as a Diagnostic and Therapeutic Target in NSCLC and Thyroid Cancer

Pathology Essentials: RET as a Diagnostic and Therapeutic Target in NSCLC and Thyroid Cancer


Tuesday, March 3, 2020

Registration: 5:30 AM - 6:00 AM
Symposium: 6:00 AM - 7:45 AM

Location:
Los Angeles Convention Center

Meeting Room 515 A
1201 S Figueroa St, Los Angeles, CA 90015
Phone: (213) 741-1151

Registration

This is a satellite symposium hosted by Physicians' Education Resource®, LLC, at the United States & Canadian Academy of Pathology (USCAP) annual meeting. Your registration to USCAP is required to attend our meeting. For more info go to http://uscap2020.com/

Overview

Methods to test non–small cell lung cancer (NSCLC), medullary thyroid carcinoma, and papillary thyroid carcinoma for RET alterations continues to evolve in parallel with empirical investigation of the clinical significance for prognosis and targeted treatment planning. Clinical decision making based on results of tumor testing informs the best treatment regimen via identification of the RET alterations at initial diagnosis, as well as testing to monitor clinical progress. As practice patterns continue to evolve, education on how to optimally test for and manage solid tumors with RET alterations in frontline and subsequent lines of therapy, and practical approaches to mitigate the impact of treatment-related toxicities, are clearly needed for pathologists and other clinicians who manage these patients.

This satellite symposium at the United States and Canadian Academy of Pathology (USCAP) 109th Annual Meeting will follow an educational format that incorporates case discussions that demonstrate real-world application of data, and the various clinical questions pathologists need to be considering. The program is led by multidisciplinary faculty who are oncology pathologists and medical oncologists.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Lilly.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com

Target Audience

This educational program is directed toward pathologists who diagnose patients with solid tumors. Other healthcare professionals involved in the diagnosis and management of patients with solid tumors are also invited to participate.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  • Identify the role of RET alterations in diagnosis, prognosis, and guiding treatment for NSCLC and thyroid cancer.
  • Evaluate safety and efficacy data for available and emerging RET-targeted treatment options in NSCLC and thyroid cancer.
  • Discuss evidence-based best practices in pathology for identifying RET alterations in NSCLC and thyroid cancer.
  • Integrate current and emerging testing techniques for RET alterations into clinical scenarios for NSCLC and thyroid cancer.

Program Chair

Marc Ladanyi
Marc Ladanyi, MD
Chief, Molecular Diagnostics Service
William J. Ruane Chair in Molecular Oncology
Memorial Sloan Kettering Cancer Center
New York, NY



Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By